Rubens Belfort Jr.
Quick facts
Marketed products
- Triamcinolone + Bevacizumab · Ophthalmology
Triamcinolone reduces inflammation via glucocorticoid receptor activation, while bevacizumab inhibits vascular endothelial growth factor (VEGF) to suppress neovascularization and reduce vascular permeability.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: